Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot. But as scrutiny builds ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

What To Watch For. Moderna, Pfizer’s mRNA vaccine rival, is also trailing its own mRNA-based flu vaccine. It launched Phase 3 trials in June and is one of the company’s most advanced vaccine ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.

Researchers for a universal flu vaccine based on mRNA technology are beginning to enroll volunteers in an early-stage clinical trial. The National Institute of Allergy and Infectious Diseases ...

An experimental influenza vaccine developed using mRNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals.